CA3047168A1 - Method for treating coronary atherosclerosis and complications thereof - Google Patents

Method for treating coronary atherosclerosis and complications thereof Download PDF

Info

Publication number
CA3047168A1
CA3047168A1 CA3047168A CA3047168A CA3047168A1 CA 3047168 A1 CA3047168 A1 CA 3047168A1 CA 3047168 A CA3047168 A CA 3047168A CA 3047168 A CA3047168 A CA 3047168A CA 3047168 A1 CA3047168 A1 CA 3047168A1
Authority
CA
Canada
Prior art keywords
plasminogen
atherosclerosis
subject
drug
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3047168A
Other languages
English (en)
French (fr)
Inventor
Jinan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen International Ltd
Original Assignee
Talengen International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen International Ltd filed Critical Talengen International Ltd
Publication of CA3047168A1 publication Critical patent/CA3047168A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3047168A 2016-12-15 2017-06-19 Method for treating coronary atherosclerosis and complications thereof Pending CA3047168A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110172 2016-12-15
CN2016110168 2016-12-15
CNPCT/CN2016/110168 2016-12-15
CNPCT/CN2016/110172 2016-12-15
PCT/CN2017/089044 WO2018107685A1 (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法

Publications (1)

Publication Number Publication Date
CA3047168A1 true CA3047168A1 (en) 2018-06-21

Family

ID=62557882

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3047168A Pending CA3047168A1 (en) 2016-12-15 2017-06-19 Method for treating coronary atherosclerosis and complications thereof
CA3046664A Active CA3046664C (en) 2016-12-15 2017-06-19 Method for preventing and treating fat metabolism disorder and related conditions thereof using plasminogen
CA3047169A Abandoned CA3047169A1 (en) 2016-12-15 2017-06-19 Method for preventing and treating fatty liver
CA3047167A Abandoned CA3047167A1 (en) 2016-12-15 2017-06-19 Method for treating and preventing atherosclerosis and complications thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3046664A Active CA3046664C (en) 2016-12-15 2017-06-19 Method for preventing and treating fat metabolism disorder and related conditions thereof using plasminogen
CA3047169A Abandoned CA3047169A1 (en) 2016-12-15 2017-06-19 Method for preventing and treating fatty liver
CA3047167A Abandoned CA3047167A1 (en) 2016-12-15 2017-06-19 Method for treating and preventing atherosclerosis and complications thereof

Country Status (7)

Country Link
US (4) US11478535B2 (enExample)
EP (4) EP3556393A4 (enExample)
JP (4) JP7161217B2 (enExample)
CN (4) CN110167583A (enExample)
CA (4) CA3047168A1 (enExample)
TW (9) TW201822805A (enExample)
WO (8) WO2018107690A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
DK4112069T3 (da) * 2020-02-26 2025-09-29 Talengen Int Ltd Komponenter i plasminogen-aktiveringsvejen til brug ved behandling af forhøjet blodtryk
CN115666612A (zh) * 2020-03-24 2023-01-31 泰伦基国际有限公司 一种治疗亨廷顿病的方法和药物
EP4140498A4 (en) 2020-05-11 2023-11-01 Talengen International Limited Method and drug for treating spinal muscular atrophy
CN112056563A (zh) * 2020-09-15 2020-12-11 王胜林 用于修复脂质代谢障碍的营养素组合物及其应用
CN113041247A (zh) * 2021-04-21 2021-06-29 中山大学孙逸仙纪念医院 伊玛替尼在防治新型冠状病毒及并发症药物中的应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4245051A (en) 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
DE3515869A1 (de) 1985-05-03 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung optisch aktiver azolderivate
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK125693D0 (enExample) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JP2002510209A (ja) 1997-06-26 2002-04-02 カロリンスカ イノベイションズ アクチボラゲット インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
AU3605800A (en) * 1999-02-24 2000-09-14 Henry Ford Health System An anti-angiogenic kringle protein and its mutants
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
WO2002040510A2 (en) * 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
ATE415412T1 (de) * 2001-08-10 2008-12-15 Novartis Pharma Gmbh Peptide, die atherosklerotische schädigungen binden
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CN1408431A (zh) 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
JP2005525798A (ja) 2002-02-06 2005-09-02 トロムスドルフ ゲーエムベーハー ウント コー．カーゲー アルツナイミッテル 微生物内での組み換えタンパク質の生産方法
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004041155A2 (en) 2002-05-13 2004-05-21 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
CN101518535A (zh) 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
WO2005026127A1 (ja) 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
US20080017694A1 (en) 2003-09-24 2008-01-24 Alexander Schnell Braze Alloy And The Use Of Said Braze Alloy
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
MXPA06012236A (es) 2004-04-22 2007-01-31 Talecris Biotherapeutics Inc Plasmina modificada en forma recombinante.
US8357147B2 (en) 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
WO2006095713A1 (ja) 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
CA2602946A1 (en) * 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20090123582A1 (en) 2006-03-24 2009-05-14 Akiko Kuwahara Ameliorating Agent for Metabolic Syndrome
WO2008026999A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
WO2008027000A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
US20110071107A1 (en) 2006-10-20 2011-03-24 Stephanie K Lynch Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
CN101015686B (zh) 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
US20080200387A1 (en) * 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
AR067446A1 (es) 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
AT505574B1 (de) * 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
RU2010120675A (ru) 2007-10-23 2011-11-27 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор продуцирования pai-1
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
CA2711878A1 (en) * 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function and methods of their use
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
US20100209350A1 (en) * 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
US20120053222A1 (en) 2009-01-23 2012-03-01 Mark Gorrell Novel Metabolic Disease Therapy
US8785473B2 (en) * 2009-03-31 2014-07-22 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
WO2010125148A2 (en) 2009-04-30 2010-11-04 Catherine Blondel Methods for treating ocular conditions
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
DK2464371T3 (en) 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CN101897925B (zh) * 2009-12-16 2015-04-29 成都百康医药工业药理毒理研究院 一种治疗代谢综合症的药物组合物
US20120114652A1 (en) 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
US9044458B2 (en) * 2010-08-09 2015-06-02 The Johns Hopkins University Inhibition of tat activating regulatory DNA-binding protein 43
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US9078904B2 (en) * 2011-02-10 2015-07-14 Trustees Of Dartmouth College Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
EP2680837A4 (en) 2011-03-03 2015-06-03 Tersus Pharmaceuticals Llc COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
CN102199587B (zh) 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
US9029321B2 (en) 2011-03-30 2015-05-12 Board Of Regents Of The University Of Texas Methods and compositions for targeting adipose cells in mammals
CN102188699A (zh) 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
US20120058537A1 (en) 2011-07-27 2012-03-08 Fereidoun Mahboudi Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102532326B (zh) * 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
CN103656630B (zh) 2012-09-11 2015-07-08 江苏仁寿药业有限公司 一种提纯动物药材中纤溶酶并制备成中药组合物的方法
WO2014070983A1 (en) 2012-10-31 2014-05-08 The Regents Of The University Of Michigan Plasminogen activator-1 inhibitors and methods of use thereof
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
US20140284520A1 (en) * 2013-03-20 2014-09-25 Elevance Renewable Sciences, Inc. Acid catalyzed oligomerization of alkyl esters and carboxylic acids
CN104274449A (zh) 2013-07-11 2015-01-14 无锡信达医疗器械有限公司 治疗肥胖症的药物组合物
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
EA033403B1 (ru) 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
US20160199466A1 (en) 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
TW201940191A (zh) * 2015-12-18 2019-10-16 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肝組織損傷及其相關病症的方法
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
TWI868051B (zh) 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Also Published As

Publication number Publication date
CA3046664A1 (en) 2018-06-21
TW201822805A (zh) 2018-07-01
WO2018107690A1 (zh) 2018-06-21
TW201822791A (zh) 2018-07-01
JP7158740B2 (ja) 2022-10-24
EP3556393A1 (en) 2019-10-23
TWI750189B (zh) 2021-12-21
US20190351033A1 (en) 2019-11-21
WO2018107684A1 (zh) 2018-06-21
JP7161217B2 (ja) 2022-10-26
US11547746B2 (en) 2023-01-10
US20190328850A1 (en) 2019-10-31
TW201822799A (zh) 2018-07-01
JP7160351B2 (ja) 2022-10-25
TWI684459B (zh) 2020-02-11
CN110114083A (zh) 2019-08-09
CN110366425A (zh) 2019-10-22
TW202123963A (zh) 2021-07-01
WO2018107692A1 (zh) 2018-06-21
EP3556391A4 (en) 2020-09-09
TW201822809A (zh) 2018-07-01
JP2020502156A (ja) 2020-01-23
EP3556387A4 (en) 2020-09-09
TWI680764B (zh) 2020-01-01
JP2020510627A (ja) 2020-04-09
CA3046664C (en) 2024-01-02
TWI746580B (zh) 2021-11-21
CA3047167A1 (en) 2018-06-21
US11478535B2 (en) 2022-10-25
JP7214225B2 (ja) 2023-01-30
EP3556394A4 (en) 2020-11-25
EP3556391A1 (en) 2019-10-23
WO2018107685A1 (zh) 2018-06-21
WO2018107691A1 (zh) 2018-06-21
CN110114082A (zh) 2019-08-09
JP2020502154A (ja) 2020-01-23
TW201822806A (zh) 2018-07-01
WO2018107687A1 (zh) 2018-06-21
CN110167583A (zh) 2019-08-23
US20200085920A1 (en) 2020-03-19
EP3556387A1 (en) 2019-10-23
EP3556394A1 (en) 2019-10-23
EP3556393A4 (en) 2020-11-25
TW201822812A (zh) 2018-07-01
JP2020511416A (ja) 2020-04-16
TW201822810A (zh) 2018-07-01
US20200078449A1 (en) 2020-03-12
WO2018107686A1 (zh) 2018-06-21
TW201822792A (zh) 2018-07-01
WO2018107688A1 (zh) 2018-06-21
CA3047169A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US11547746B2 (en) Method for treating coronary atherosclerosis and complications thereof
US11090372B2 (en) Method of treating diabetic nephropathy comprising administering plasminogen
US11389515B2 (en) Method for mitigating heart disease
HK1257234A1 (zh) 治疗冠状动脉粥样硬化及其并发症的药物及其用途
US11219669B2 (en) Method for preventing and treating liver fibrosis
HK1257238A1 (zh) 预防和治疗脂质肾损伤的药物及其用途
CA3046666C (en) Method for preventing and treating tissue and organ fibrosis
HK1257235A1 (en) Medicine for treating atherosclerosis and complications of atherosclerosis and use of the medicine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190614

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250521

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331